Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

bmiMD vs RxPepsDirect

By GLP-1 ScorecardUpdated

bmiMDFactor scores not reassessed.
Site position #27

Higher score

RxPepsDirectFactor scores not reassessed.
Site position #156

Lower score

Score comparison

bmiMD has the higher recorded score — 79.2/100 to 68.7/100.

bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.

Before you choose

Before comparing the headline prices, the bmiMD review and the RxPepsDirect review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, bmiMD vs RxPros and Care Clinics vs RxPepsDirect compare each of them with another graded program, and the list of alternatives to bmiMD ranks the programs closest to bmiMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valuebmiMD +2
88
86
Dose & formulationbmiMD +18
82
64
Clinical oversightbmiMD +1
70
69
Labs & monitoringbmiMD +20
72
52
FulfillmentbmiMD +14
84
70
Contract termsbmiMD +19
74
55
bmiMD · top barRxPepsDirect · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricbmiMDRxPepsDirect
WeighScore79.2/10068.7/100
GradeC+C
Site position#27#156
Semaglutide$129/mo on the one-month plan ($99/mo equivalent with $1,188 prepaid for 12 months)$63.60 starting order (compounded semaglutide/B12, $9.60 vial + $39 medical review + $15 shipping)
Tirzepatide$179/mo on the one-month plan ($139/mo equivalent with $1,668 prepaid for 12 months)$90 starting order (compounded tirzepatide/B12, $36 vial + $39 medical review + $15 shipping)
CoverageAll 50 states28 states plus DC
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesNot confirmed
bmiMD

Site position #27 · C+

Factor scores not reassessed.

Strengths

  • Advertises the same price across prescribed doses for each selected injection plan
  • Publishes compounded semaglutide and tirzepatide injection plans
  • Every rung of both ladders is published with the total charge beside each per-month figure
  • All 50 states

What to consider

  • The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
  • The annual $99 and $139 monthly equivalents require $1,188 or $1,668 paid upfront for 12 months
  • A higher $229 and $349 monthly figure is printed beside every plan price under a standing LIMITED TIME label, with no published basis
  • Neither the compounding pharmacy nor the prescribing group is named on the product pages
RxPepsDirect

Site position #156 · C

Factor scores not reassessed.

Strengths

  • Full semaglutide/B12 and tirzepatide/B12 vial price ladders are public
  • No membership; automatic refills are optional and can be disabled in the dashboard
  • Publishes sample sterility and endotoxin reports from an outside laboratory

What to consider

  • Starting-order totals are not guaranteed ongoing monthly treatment prices
  • The $39 visit fee recurs per order and is nonrefundable once clinical review begins, even if denied
  • Pharmacy payments have separate refund terms
  • Product pages describe a Texas 503A pharmacy without naming it
  • Compounded protocols and testing reports do not establish FDA approval or equivalence to branded trial results

Featured provider

bmiMD

Factor scores not reassessed.

bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard